TY - JOUR
T1 - Heterogeneous pulmonary phenotypes associated with mutations in the thyroid transcription factor gene NKX2-1
AU - Hamvas, Aaron
AU - Deterding, Robin R.
AU - Wert, Susan E.
AU - White, Frances V.
AU - Dishop, Megan K.
AU - Alfano, Danielle N.
AU - Halbower, Ann C.
AU - Planer, Benjamin
AU - Stephan, Mark J.
AU - Uchida, Derek A.
AU - Williames, Lee D.
AU - Rosenfeld, Jill A.
AU - Lebel, Robert Roger
AU - Young, Lisa R.
AU - Cole, F. Sessions
AU - Nogee, Lawrence M.
N1 - Funding Information:
Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Ms Rosenfeld is employed by Signature Genomics Laboratories, a subsidiary of PerkinElmer, Inc. Dr Halbower receives grant money from the Children's Hospital Colorado Foundation and the Department of Pediatrics. She is a medical consultant for AVISA Pharma Inc, paid (in the future) by stock options. The other authors have no conflicts of interest to declare.
PY - 2013/9
Y1 - 2013/9
N2 - Background: Mutations in the gene encoding thyroid transcription factor, NKX2-1, result in neurologic abnormalities, hypothyroidism, and neonatal respiratory distress syndrome (RDS) that together are known as the brain-thyroid-lung syndrome. To characterize the spectrum of associated pulmonary phenotypes, we identifi ed individuals with mutations in NKX2-1 whose primary manifestation was respiratory disease. Methods: Retrospective and prospective approaches identifi ed infants and children with unexplained diffuse lung disease for NKX2-1 sequencing. Histopathologic results and electron micrographs were assessed, and immunohistochemical analysis for surfactant-associated proteins was performed in a subset of 10 children for whom lung tissue was available. Results: We identifi ed 16 individuals with heterozygous missense, nonsense, and frameshift mutations and fi ve individuals with heterozygous, whole-gene deletions of NKX2-1 . Neonatal RDS was the presenting pulmonary phenotype in 16 individuals (76%), interstitial lung disease in four (19%), and pulmonary fi brosis in one adult family member. Altogether, 12 individuals (57%) had the full triad of neurologic, thyroid, and respiratory manifestations, but fi ve (24%) had only pulmonary symptoms at the time of presentation. Recurrent respiratory infections were a prominent feature in nine subjects. Lung histopathology demonstrated evidence of disrupted surfactant homeostasis in the majority of cases, and at least fi ve cases had evidence of disrupted lung growth. Conclusions: Patients with mutations in NKX2-1 may present with pulmonary manifestations in the newborn period or during childhood when thyroid or neurologic abnormalities are not apparent. Surfactant dysfunction and, in more severe cases, disrupted lung development are likely mechanisms for the respiratory disease.
AB - Background: Mutations in the gene encoding thyroid transcription factor, NKX2-1, result in neurologic abnormalities, hypothyroidism, and neonatal respiratory distress syndrome (RDS) that together are known as the brain-thyroid-lung syndrome. To characterize the spectrum of associated pulmonary phenotypes, we identifi ed individuals with mutations in NKX2-1 whose primary manifestation was respiratory disease. Methods: Retrospective and prospective approaches identifi ed infants and children with unexplained diffuse lung disease for NKX2-1 sequencing. Histopathologic results and electron micrographs were assessed, and immunohistochemical analysis for surfactant-associated proteins was performed in a subset of 10 children for whom lung tissue was available. Results: We identifi ed 16 individuals with heterozygous missense, nonsense, and frameshift mutations and fi ve individuals with heterozygous, whole-gene deletions of NKX2-1 . Neonatal RDS was the presenting pulmonary phenotype in 16 individuals (76%), interstitial lung disease in four (19%), and pulmonary fi brosis in one adult family member. Altogether, 12 individuals (57%) had the full triad of neurologic, thyroid, and respiratory manifestations, but fi ve (24%) had only pulmonary symptoms at the time of presentation. Recurrent respiratory infections were a prominent feature in nine subjects. Lung histopathology demonstrated evidence of disrupted surfactant homeostasis in the majority of cases, and at least fi ve cases had evidence of disrupted lung growth. Conclusions: Patients with mutations in NKX2-1 may present with pulmonary manifestations in the newborn period or during childhood when thyroid or neurologic abnormalities are not apparent. Surfactant dysfunction and, in more severe cases, disrupted lung development are likely mechanisms for the respiratory disease.
UR - http://www.scopus.com/inward/record.url?scp=84884331670&partnerID=8YFLogxK
U2 - 10.1378/chest.12-2502
DO - 10.1378/chest.12-2502
M3 - Article
C2 - 23430038
AN - SCOPUS:84884331670
SN - 0012-3692
VL - 144
SP - 794
EP - 804
JO - CHEST
JF - CHEST
IS - 3
ER -